Indraprastha Medical Corporation Q3FY26 Results

Indraprastha Medical Corporation reported Q3FY26 revenue of ₹378.76 crore and net profit of ₹41.00 crore. Nine-month revenue reached ₹1159.12 crore with net profit of ₹141.92 crore.

Indraprastha Medical Corp Reports Revenue Growth to Rs 3.8B in Q2

Indraprastha Medical Corp reported Q2 revenue of Rs 3.8 billion, up from Rs 3.5 billion in the same quarter last year. The company's EBITDA increased to Rs 713 million from Rs 636 million year-over-year. EBITDA margin improved to 18.72% compared to 18.19% in the previous year's corresponding quarter.

Indraprastha Medical Corp Reports 16.6% Growth in Net Profit

Indraprastha Medical Corp reported a net profit of Rs 494.6 million for Q2, compared to Rs 424 million in the same period last year, representing a year-on-year increase of 16.6%.

Indraprastha Medical Hits All-Time High on CGHS Tariff Revision

Indraprastha Medical Corporation shares reached an all-time high of Rs 624, gaining over 30% in two days and nearly 40% over five trading sessions. The rally follows the Central Government Health Services announcing its biggest tariff revision in 15 years, increasing package rates for nearly 2,000 medical procedures by 5-30%, particularly benefiting specialties like orthopaedics, cardiology, and oncology. The company, a joint venture between Apollo Hospitals and Delhi government, expects higher CGHS-linked revenues and improved average revenue per occupied bed from the tariff hike. The stock has gained 15% year-to-date and 44% over 12 months, though it's trading with an RSI of 82, indicating potential overbought conditions.

Indraprastha Medical Corporation Reports Q1 Results and Key Board Appointments

Indraprastha Medical Corporation Limited approved its unaudited financial results for the quarter ended June 30, 2025. The company reported revenue from operations of Rs 365.06 crore compared to Rs 347.86 crore in the same quarter last year, with profit after tax increasing to Rs 51.46 crore from Rs 44.77 crore year-on-year. Earnings per share stood at Rs 5.61 versus Rs 4.88 in the previous year quarter. The Board appointed Mr. Sudhir Jalan as an Independent Director for a five-year term from August 6, 2025 to August 5, 2030, subject to shareholder approval. The company scheduled its 37th Annual General Meeting for September 24, 2025, and fixed the record date as September 18, 2025 for dividend entitlement for 2024-25. Additionally, the Board re-appointed M/s Devarajan Swaminathan and Co. as Cost Auditors for 2025-26 and appointed M/s RSM & Co. as Secretarial Auditors for five years from 2025-26 to 2029-30, both subject to shareholder approval.